In line with data from studies in normal individuals [25], [26] and patients with frontotemporal lobar degeneration [27], breast [17] and ovarian cancer [18], we found that Pgrn can be easily and reliably measured in the peripheral blood employing a commercially available enzyme-linked immunosorbent assay. This evidence concerns the gene GRN and ovarian cancer.